Company intelligence / Profile preview

DiagnoCure Oncology Laboratories

Quebec City, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

DiagnoCure was a Canadian life sciences company specializing in the development and commercialization of high-value cancer diagnostic tests. The company is best known for developing the PCA3 test for prostate cancer, which was licensed to Gen-Probe (now Hologic), and the Previstage GCC colorectal cancer staging test. DiagnoCure focused on molecular biomarkers to improve the detection and management of various cancers, including prostate, colorectal, and bladder. Following a strategic review and the sale of its primary assets, the company initiated a formal liquidation and dissolution process in 2016.

Therapeutic areas: Oncology
Modalities: Molecular diagnosticsBiomarker-based assay
Industry: Molecular Diagnostics

Partnerships

HologicGen-ProbeLabCorpScican

Beyond the preview

Go deeper on DiagnoCure Oncology Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiagnoCure Oncology Laboratories.

Explore the full profile